Tuesday's Health Winners & Losers
An overall blase Tuesday for health stocks was peppered with conservative outlooks, anticipation of a Food and Drug Administration advisory panel and analyst speculation.
Merck (MRK) offered guidance for 2007 that met its prior expectations of between $3.08 and $3.14 a share (before the $4.85 billion Vioxx settlement) but is now below the expectations of analyst polled by Thomson Financial, who were looking for $3.15 a share. The company also said 2008 earnings should rise, but its projected range was $3.28 and $3.38 a share, excluding one-time items. The Thomson Financial consensus target for 2008 was $3.39 a share.
Shares edged down 38 cents, or 0.7%, to $58.39. Merck is a component of the Amex pharmaceutical index, which down 0.3% at 353.22.
Meanwhile, investors were still antsy ahead of a Wednesday FDA advisory panel for Genentech's (DNA) Avastin with Paclitaxel for breast cancer. The panel will discuss whether a 5.5-month improvement in progression-free survival is sufficient to approve the drug without an improvement in overall survival. On higher-than-average volume, shares were down 72 cents, or 1%, at $72.78.Repros Therapeutics (RPRX) said Tuesday that, based on its meeting with the FDA, uterine fibroid-induced anemia is a new indication for Proellex, and the company plans to begin pivotal phase III trials during the first quarter of 2008 with a goal of filing a new-drug application (NDA) by the end of 2008. The company said that it will submit an investigational new-drug application (IND) as soon possible to begin two pivotal phase III trials for Proellex as a presurgical treatment for anemia associated with excessive bleeding due to uterine fibroids, or tumors that grow within the wall of the uterus, as soon as possible. The company said it also discussed conducting clinical trials for the indication as a short-course treatment of anemia due to excessive menstrual bleeding due to uterine fibroids. Shares traded up 43 cents, or 5.3%, to $8.50.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV